A Phase Ib, Open Label, Multi-center Study to Characterize the Safety, Tolerability and Preliminary Efficacy of EGF816 in Combination With Selected Targeted Agents in EGFR Mutant NSCLC
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Nazartinib (Primary) ; Capmatinib; Gefitinib; LXH 254; Ribociclib; Trametinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 30 Jan 2018 Status changed from not yet recruiting to recruiting.
- 22 Jan 2018 Planned End Date changed from 23 Apr 2021 to 21 May 2021.
- 22 Jan 2018 Planned primary completion date changed from 23 Apr 2021 to 21 May 2021.